Related Experiment Video
Updated: Jun 15, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era
Peter F Aziz1, Ronn E Tanel, Ilana J Zelster
1Division of Cardiology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. aziz@email.chop.edu
Insights
Infants with congenital long QT syndrome (LQTS) and 2:1 atrioventricular block (AVB) have a better outlook with modern management. Early diagnosis and intervention improved outcomes in this high-risk group.
Area of Science:
- Pediatric Cardiology
- Clinical Electrophysiology
- Genetics
Background:
- Congenital long QT syndrome (LQTS) with 2:1 atrioventricular block (AVB) historically carries a >50% infant mortality.
- This high-risk population requires updated prognostic evaluation.
Purpose of the Study:
- To determine the current outcomes for infants diagnosed with congenital LQTS and 2:1 AVB.
- To assess the effectiveness of contemporary management strategies.
Main Methods:
- Retrospective analysis of 12 neonates with congenital LQTS and 2:1 AVB from 2000-2009 across four pediatric centers.
- Review of ECG, QTc intervals, genotype, medications, and device therapies.
- Statistical analysis including paired t-test.
Main Results:
- No mortality observed in the cohort over a median follow-up of 71 months.
- 11 of 12 patients received cardiac device therapy (pacemaker or ICD).
- Significant reduction in QTc intervals post-intervention (mean 480 ms vs. 616 ms).
Conclusions:
- Contemporary management of LQTS with 2:1 AVB offers a more optimistic prognosis than previously reported.
- Early diagnosis, intervention, and improved therapeutic strategies contribute to favorable outcomes.
- This study highlights the importance of proactive management in this challenging pediatric condition.
Background:
Previous studies of patients with long QT syndrome (LQTS) and 2:1 atrioventricular block (AVB) have reported a mortality rate greater than 50% during infancy.
Objective:
The purpose of this study was to determine the outcome of this high-risk population in the current era.
Methods:
A retrospective study from four tertiary care pediatric centers assessed patients with congenital LQTS and 2:1 AVB from January 2000 to January 2009. All neonates who presented with 2:1 AVB and prolonged QTc unrelated to medication were included in the study. Statistical analysis was performed using a paired t-test. Medical records were reviewed for ECG findings, genotype, medications, and device therapy.
Results:
Twelve patients that met the inclusion criteria were identified. All patients underwent diagnostic ECG in the first 24 hours of life. The average QTc interval prior to therapy was 616 +/- 99 ms (range 531-840 ms). Over a follow-up period of 71 +/- 45 months (range 15-158 months), 11 of 12 patients received devices (8 permanent pacemaker, 3 implantable cardioverter-defibrillator). Average age of device placement was 48 months (median 2 months, range 3 days to 10.5 years). All patients were treated with beta-blockers; mexiletine was added in three patients, and mexiletine and flecainide were added in one patient. Three (25%) patients experienced torsades de pointes while receiving beta-blockers, one of which was refractory to medical therapy. This patient underwent left cardiac sympathetic denervation and implantable cardioverter-defibrillator placement. Genotyping was available for 6 (50%) patients (2 SCN5A mutation, 4 KCNH2 mutation). At last follow-up, no mortality was observed. Follow-up QTc intervals had decreased (mean 480 +/- 20 ms, range 450-507 ms, P <.002).
Conclusion:
Management of patients with LQTS and 2:1 AVB presents unique challenges. Despite historical data indicating poor prognosis, our study represents a cohort of high-risk LQTS patients with a relatively optimistic outcome. This finding reflects early diagnosis and intervention, coupled with improved management strategies, in the current era.
Related Concept Videos
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias
